Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: A multicenter, randomized, double-blind, placebo-controlled trial

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Miki, Keisuke ^a   Maekura, Ryoji ^a   Nagaya, Noritoshi ^b   Nakazato, Masamitsu ^c   Kimura, Hiroshi ^d   Murakami, Shinsuke ^d   Ohnishi, Shunsuke ^b   Hiraga, Toru ^a   Miki, Mari ^a   Kitada, Seigo ^a   Yoshimura, Kenji ^a   Tateishi, Yoshitaka ^a   Arimura, Yasuji ^c   Matsumoto, Nobuhiro ^c   Yoshikawa, Masanori ^d   Yamahara, Kenichi ^b   Kangawa, Kenji ^b  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GHRELIN; GROWTH HORMONE; METHYLXANTHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO;

ABNORMAL SENSATION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BREATHING MUSCLE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE TOLERANCE; FEMALE; FOOD INTAKE; FORCED EXPIRATORY VOLUME; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUNGER; HYPERCHOLESTEROLEMIA; HYPOPROTEINEMIA; LIVER DYSFUNCTION; LUNG DISEASE; LUNG GAS EXCHANGE; MALE; MEDICAL RESEARCH COUNCIL SCALE; MULTICENTER STUDY; MUSCLE STRENGTH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PULMONARY CACHEXIA; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; SIDE EFFECT; STOMACH DISEASE; STOMACH RUMBLING; THIRST; TREATMENT DURATION; TREATMENT OUTCOME; WALKING; WARMTH SENSATION; WEIGHT GAIN; BLOOD; CACHEXIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PNEUMONIA; QUALITY OF LIFE; QUESTIONNAIRE; TIME;

AGED; AGED, 80 AND OVER; CACHEXIA; COMBINED MODALITY THERAPY; DEPRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GHRELIN; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 84860454868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035708     Document Type: Article

References (35)

1. Wagner PD, (2008) Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 31: 492-501.
2. Wilson DO, Rogers RM, Wright EC, Anthonisen NR, (1989) Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 139: 1435-1438.
3. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting JW, (1997) Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 156: 1800-1806.
4. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, et al. (2007) Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 131: 4S-42S.
5. Zinna EM, Yarasheski KE, (2003) Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care 6: 87-93.
6. Zaloga GP, (2005) Ghrelin, diet, and pulmonary function. Chest 128: 1084-1086.
7. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
8. Tschop M, Smiley DL, Heiman ML, (2000) Ghrelin induces adiposity in rodents. Nature 407: 908-913.
9. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-198.
10. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M, (2002) Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 40: 694-699.
11. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, et al. (2001) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280: R1483-1487.
12. Itoh T, Nagaya N, Yoshikawa M, Fukuoka A, Takenaka H, et al. (2004) Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 879-882.
13. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, et al. (2005) Treatment of cachexia with ghrelin in patients with COPD. Chest 128: 1187-1193.
14. Jones PW, Quirk FH, Baveystock CM, Littlejohns P, (1992) A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145: 1321-1327.
15. Ware JE Jr, Sherbourne CD, (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483.
16. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K, (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51: 1037-1044.
17. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B, (1998) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51: 1045-1053.
18. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH, (1959) The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 2: 257-266.
19. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW, (2003) Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 124: 1350-1356.
20. Rabinovich RA, Ardite E, Mayer AM, Polo MF, Vilaro J, et al. (2006) Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. Respiration 73: 757-761.
21. Puhan MA, Schunemann HJ, Frey M, Scharplatz M, Bachmann LM, (2005) How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax 60: 367-375.
22. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, et al. (2007) Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146: 104-115.
23. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, et al. (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124: 708-716.
24. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, et al. (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288: 2282-2292.
25. Anawalt BD, Merriam GR, (2001) Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metab Clin North Am 30: 647-669.
26. Lamberts SW, van den Beld AW, van der Lely AJ, (1997) The endocrinology of aging. Science 278: 419-424.
27. Creutzberg EC, Wouters EF, Mostert R, Pluymers RJ, Schols AM, (2003) A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 124: 1733-1742.
28. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, et al. (2007) Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. Int J Cardiol 119: 83-89.
29. Lutter M, Elmquist J, (2009) Depression and metabolism: linking changes in leptin and ghrelin to mood. F1000 Biol Rep 1.
30. Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, et al. (2004) Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150: 447-455.
31. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, et al. (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110: 3674-3679.
32. Cassoni P, Allia E, Marrocco T, Ghe C, Ghigo E, et al. (2006) Ghrelin and cortistatin in lung cancer: expression of peptides and related receptors in human primary tumors and in vitro effect on the H345 small cell carcinoma cell line. J Endocrinol Invest 29: 781-790.
33. Belloni AS, Macchi C, Rebuffat P, Conconi MT, Malendowicz LK, et al. (2004) Effect of ghrelin on the apoptotic deletion rate of different types of cells cultured in vitro. Int J Mol Med 14: 165-167.
34. Ghe C, Cassoni P, Catapano F, Marrocco T, Deghenghi R, et al. (2002) The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology 143: 484-491.
35. Murata M, Okimura Y, Iida K, Matsumoto M, Sowa H, et al. (2002) Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 277: 5667-5674.